Trials / Conditions / Unresectable Gastroesophageal Junction Adenocarcinoma

Unresectable Gastroesophageal Junction Adenocarcinoma

15 registered clinical trials studyying Unresectable Gastroesophageal Junction Adenocarcinoma — 8 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in P NCT06364410	National Cancer Institute (NCI)	Phase 1
Recruiting	Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial NCT06203600	National Cancer Institute (NCI)	Phase 2 / Phase 3
Recruiting	A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People Wit NCT06251973	Memorial Sloan Kettering Cancer Center	Phase 2
Recruiting	Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Loca NCT05651594	Roswell Park Cancer Institute	Phase 2
Recruiting	mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastati NCT05677490	Alliance for Clinical Trials in Oncology	Phase 3
Recruiting	Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Soli NCT05269381	Mayo Clinic	Phase 1 / Phase 2
Recruiting	Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adeno NCT05041153	M.D. Anderson Cancer Center	EARLY_Phase 1
Active Not Recruiting	Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advance NCT04391049	NRG Oncology	Phase 1
Recruiting	Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tu NCT04704661	National Cancer Institute (NCI)	Phase 1
Active Not Recruiting	Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Eso NCT04460937	National Cancer Institute (NCI)	Phase 1
Active Not Recruiting	Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gast NCT03641313	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer NCT04522336	M.D. Anderson Cancer Center	Phase 1
Withdrawn	MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma NCT03739801	University of Southern California	Phase 1 / Phase 2
Completed	Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma NCT03395847	M.D. Anderson Cancer Center	EARLY_Phase 1
Completed	Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal NCT03008278	National Cancer Institute (NCI)	Phase 1 / Phase 2